Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Median Technologies

< Previous 1 2 3 Next >

Median Technologies Receives FDA 510(k) Clearance for eyonis® LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening

Today 1:00 EST

From Median Technologies

Via Business Wire

Median Technologies Reports Landmark 2025 Performance With Major Regulatory and Commercial Milestones Ahead in 2026

January 19, 2026

From Median Technologies

Via Business Wire

Median Technologies Partners With Leading U.S. Healthcare Company to Bring eyonis® LCS to Patients Across the U.S. and Europe

December 08, 2025

From Median Technologies

Via Business Wire

Median Technologies to Showcase AI-Powered Software as a Medical Device eyonis® LCS for Lung Cancer Screening at the RSNA 2025 Annual Meeting

November 25, 2025

From Median Technologies

Via Business Wire

Median Technologies Appoints Didric Cederholm to Its Board of Directors

November 03, 2025

From Median Technologies

Via Business Wire

Median Technologies Reports First-Half 2025 Financial Results and Provides Key Q3 2025 Business Results

October 23, 2025

From Median Technologies

Via Business Wire

Median Technologies Receives €19 Million From the European Investment Bank, Corresponding to the First Tranche Under the 2025 Loan Facility

October 21, 2025

From Median Technologies

Via Business Wire

Median Technologies Business Update Following Successful Financing

September 22, 2025

From Median Technologies

Via Business Wire

Median Technologies Signs Financial Agreement for up to €37.5 Million New Financing Facility With the European Investment Bank (EIB)

July 11, 2025

From Median Technologies

Via Business Wire

Median Technologies Files European Application for Class IIb CE Marking of Its AI-Based Software as a Medical Device for Lung Cancer Screening, eyonis® LCS

July 01, 2025

From Median Technologies

Via Business Wire

Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025

May 27, 2025

From Median Technologies

Via Business Wire

Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS

May 14, 2025

From Median Technologies

Via Business Wire

Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025

May 12, 2025

From Median Technologies

Via Business Wire

Median Technologies Reports Full-year 2024 Financial Results

April 29, 2025

From Median Technologies

Via Business Wire

Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements

April 24, 2025

From Median Technologies

Via Business Wire

eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study

March 31, 2025

From Median Technologies

Via Business Wire

Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference

February 26, 2025

From Median Technologies

Via Business Wire

Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology

February 24, 2025

From Median Technologies

Via Business Wire

Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions

February 03, 2025

From Median Technologies

Via Business Wire

Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook

January 31, 2025

From Median Technologies

Via Business Wire

Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU

January 24, 2025

From Median Technologies

Via Business Wire

Median Technologies: Financial Communications Schedule for the First Half of 2025

January 14, 2025

From Median Technologies

Via Business Wire

Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024

November 26, 2024

From Median Technologies

Via Business Wire

Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis™ Lung Cancer Screening (LCS) REALITY Data

November 07, 2024

From Median Technologies

Via Business Wire

Median Technologies to Host Key Opinion Leader (KOL) Webinar on AI and Lung Cancer Screening

October 30, 2024

From Median Technologies

Via Business Wire

Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results

October 24, 2024

From Median Technologies

Via Business Wire

Median Technologies to Attend and Present at the ESMO Congress 2024, Being Held in Barcelona, Spain, from Sept 13-17, 2024

September 11, 2024

From Median Technologies

Via Business Wire

Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software as medical device at the IASLC 2024 World Conference on Lung Cancer

September 04, 2024

From Median Technologies

Via Business Wire

Median Technologies to host two webcasts on September 5, 2024

September 02, 2024

From Median Technologies

Via Business Wire

Median Technologies Announces Pivotal REALITY Study of Its eyonis™ LCS Lung Cancer Diagnostic Met All Primary and Secondary Endpoints

August 29, 2024

From Median Technologies

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.